Exposure to replication competent lentivirus (RCL) is a theoretical safety concern for individuals treated with lentiviral gene therapy. For certain ex vivo gene therapy applications, including cancer immunotherapy trials, RCL detection assays are used to screen the vector product as well as the vector-transduced cells. In this study, we reviewed T cell products screened for RCL using methodology developed in the National Gene Vector Biorepository. All trials utilized third generation lentiviral vectors produced by transient transfection. Samples from 26 clinical trials totaling 460 transduced cell products from 375 subjects were evaluated. All cell products were negative for RCL. A total of 296 of the clinical trial participants were screened for RCL at least 1 month after infusion of the cell product. No research subject has shown evidence of RCL infection. These findings provide further evidence attesting to the safety of third generation lentiviral vectors and that testing T cell products for RCL does not provide added value to screening the lentiviral vector product.
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INTRODUCTION
Adoptive therapy with genetically modified T cells using lentiviral vectors is in advanced stages of clinical development for cancer indications by academic investigators and several companies. [1] [2] [3] [4] Commercial approval by the US Food and Drug Administration of CTL019, a CD19 CAR T cell for the therapy of relapsed leukemia is expected in 2017. In addition, several centers are testing engineered hematopoietic stem cells and other targets using gene transfer with lentiviral vector technology. [5] [6] [7] [8] [9] Thus, detection of replication competent lentivirus (RCL) is emerging as a major issue given the widespread use of lentiviral vector technology.
Detecting RCL in lentiviral vector products is a key release test to ensure patients are not inadvertently exposed to replicating virus. The most likely source of RCL virus would be recombination between vector sequences and the viral genes expressed during vector manufacture. [10] [11] [12] Detection of a vector-associated RCL is challenging given this virus is still theoretical and therefore the components of the virus are unknown. Replicating viruses have been described in the manufacture of vectors based on murine leukemia viruses (MLV). Most commonly, these MLV-derived viruses arose through recombination of vector and packaging sequences and decreasing homology between vector and packaging sequences has been shown to decrease virus formation. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Some recombinant retroviruses have also been shown to contain vector packaging sequences and cellular derived genes. 23, 24 This raises the possibility that a RCL could contain packaging sequences along with endogenous human retroviral 25 or other cellular components. This experience with MLV-based vectors has shaped FDA recommendations for recombinant virus testing, including recommendations for RCL assays.
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In the US, a lentiviral vector lot must be screened for RCL prior to clinical use. 27 Research subjects are also continuously monitored after treatment for the presence of RCL. A M A N U S C R I P T
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4 third assessment is also required for any cell product cultured ex vivo for more than 4 days, since a putative RCL that was not detected in the vector release assay may be amplified in cell culture and thus become detectable. As the majority of T cell receptor (TCR) and chimeric antigen receptor (CAR) vector trials use cell expansion, RCL screening of the infused T cell product is required for most cancer immunotherapy trials. This requirement presents challenges to the clinical development of T cell applications due to the number of cells that must be tested (1% of the cell product or 10 8 cells, whichever is less), 27, 28 the complexity of assessing RCL in high titer vector, 29 and the associated expense of screening this large number of cells.
RCL detection is also complicated by the similarity between vector and viral particles.
Many components of an RCL will be similar to a vector particle (capsid, integrase and reverse transcriptase) so most protein detection methods will not be fruitful. Similarly, assay for reverse transcriptase activity 30, 31 cannot distinguish RCL from vector particles. While vector genomes lack genes used in viral replication, these genes must be expressed in vector producing cells and any carryover of cellular or plasmid DNA into the vector product can lead to false positive molecular assays. Moreover, all non-culture assays to date lack the sensitivity of culture based assays where theoretically one infectious unit can be amplified to large numbers. 11 A number of RCL culture assays have been described including syncytia formation assays capable of detecting a fully competent lentivirus but the sensitivity of this approach in detecting an attenuated virus has not been extensively studied. 32 Marker rescue assays have also been described for HIV-1 but whether a RCL arising from vector production will mobilize the marker is unknown. 33, 34 To date, the most common assays for screening gene therapy products are assays which combine an amplification phase using a cell line capable of expanding attenuated viruses to high titer, with subsequent detection of virus using ELISA or molecular assays.
29, 35-39
Since RCL arising during vector production are still theoretical, their growth rate is unknown, but it is likely to be significantly attenuated compared to wild type lentiviruses due to the absence of accessory genes. 33 Therefore, regulators have required biologic assays to utilize an extended culture period of approximately 3 weeks (a minimum of 5 passages) 27 to amplify any slow growing viruses. Using this stringent screening method, RCL has not been reported in any research or clinical lentiviral vector preparations. The lack of RCL provides support for the overall safety of lentiviral vectors and suggests the multiple safety features incorporated in vector design are effective in limiting RCL development. 40 Since the advent of lentiviral vectors for clinical application in 2003, a conservative RCL testing approach has been implemented to allow for an optimal risk:benefit for patients, while the field gathered experience with this new vector system. It is unknown whether the testing of infused products adds additional value to the testing of the vector product. In this paper, we review the experience of the National Gene Vector Biorepository (NGVB), a NHLBI funded resource to assist investigators in meeting FDA requirements for gene therapy (www.NGVBCC.org). The NGVB has assisted investigators in testing T cell products for RCL from a variety of clinical trials. To date, none of the products tested were found to contain RCL.
The data suggests that RCL testing of infused products does not provide additional assurances of safety and that screening vector products is a sufficient release test for third generation lentiviral vectors.
RESULTS
Lentiviral vectors have much in common with native lentiviruses making it difficult to distinguish vector particles from RCL. Biologic assays which expose permissive cell lines to
vector preparations have been shown to be the preferred method of RCL detection. 11, 35, 36 In 2011, we reported our assay's methodology and performance in testing clinical vector products.
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The general components of the RCL assay used in this study are shown in Figure 1 . Subject Follow-up. Not all products screened for RCL were infused into the intended research subject due to non-RCL related issues. As shown in Table 3 , of the 460 transduced products tested for RCL, 409 were infused (89%). A number of trials utilized multiple products per subject, with the 409 products infused into 375 subjects. To help provide additional validation of the RCL testing method, subjects who underwent RCL testing at time points >30 days post-infusion were tabulated and listed in Table 2 . A total of 296 of the 375 (79%) subjects had a least one RCL test performed after infusion, all analyzes were negative for RCL. In all but one subject, RCL detection of peripheral blood was performed using a PCR for VSV-G envelope DNA.
Assay Performance. The RCL assay used in this paper is composed of two culture phases, an initial amplification phase and a second indicator phase. Culture media is tested at the Resubmitted test articles also showed inhibition and the assay was completed by increasing the number of C8166-45 cells at each passage. All resubmitted test articles discussed above completed the assay successfully and were found to be negative for RCL at the amplification and indicator phase. During review of all assays for this analysis, 2 assays were found to have a miscalculation in the number of C8166-45 cells added to the culture; the ratio of test article cell to C8166-45 was 1:4.35 which is below the minimum of 1:5 specified for this assay.
There were 8 indicator phase assays that failed to meet acceptability criteria. Three of the assays failed due to technician error. One indicator phase culture grew slowly, and repeat using reserve material also showed slow growth of C8166-45 cells; sufficient cells were available for analysis. Four indicator assays were repeated because the positive controls were negative.
Reserve amplification phase media was available for all the indicator phase assays noted above;
resubmission test articles were therefore not needed. All indicator phases cultures using reserve amplification phase media were found to be negative for RCL.
Amplification and Indicator Phase culture media is subjected to p24 ELISA analysis to identify HIV capsid protein, a predicted component of any RCL. Each test article and control is run in duplicate wells. There were no instances when both duplicate wells were positive, which is an acceptance criterion for a positive assay. There were 15 instances when one well was below and one slightly above the limits of detection; 9 occurred in a test article and 6 in a negative control samples. In all cases, repeat analysis with reserve material found the sample to be below the limits of detection (12.5 pg/mL). In addition, the test articles in question were negative by psi-gag PCR or PERT. All test articles tested by ELISA met the criteria for RCL negative samples.
Between June 2011 and March of 2013, 84 test articles were analyzed by the psi-gag PCR assay. One assay did not meet criteria due to a positive signal detected in both the test article and the negative control. The p24 ELISA result for this test article was negative in both the amplification and indicator phase. The assay was repeated and both negative control and test article were negative, test article was considered negative for RCL. After March of 2013, the PERT assay replaced psi-gag PCR. There were 3 PERT assays where the standard curve did not meet acceptability criteria and 1 assay where the positive control did not meet acceptance criteria. The assays were repeated using reserve material and met acceptance criteria. In analyzing 417 test articles by PERT, there were 4 test articles and 2 negative control test articles which were just above baseline. The corresponding p24 analysis was negative and repeat PERT testing using reserve samples was negative for reverse transcriptase. Upon retesting, all test articles met the criteria for RCL negative samples.
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DISCUSSION
Inadvertent exposure of subjects to pathogens that contaminate gene therapy products is a top safety concern. Lentiviral vectors have been designed to minimize the chance of recombination and, to date, RCL has not been detected in research materials generated with third generation vector systems. In 2011, we also showed that 16 lentiviral vector products manufactured for clinical trial use had no evidence of RCL. 29 Continued testing at the NGVB has failed to detect RCL using material submitted from a variety of manufacturing facilities. In this manuscript, we provide further evidence for the biosafety of lentiviral vector production systems.
Using a sensitive RCL assay, there was no evidence of replicating virus in 460 T cell products.
The products tested span 26 clinical trials at 6 different institutions. Follow-up analysis of treated research subjects also found no evidence of RCL. Given the lack of documented RCL in a large number of T cell products, the design features of third generation lentiviral vectors, and the lack of documented RCL in clinical vector lots, RCL testing of T cell products does not appear to provide additional assurances of safety and testing requirements should be re-evaluated. Our findings also have implications for research laboratories and suggest re-evaluation of biosafety requirements for third generation lentiviral vectors.
In developing a detection assay for RCL, we developed an assay that was exhaustive by intent. The assay uses both p24 ELISA and a molecular detection assay (psi-gag PCR or PERT)
to provide redundancy in order to minimize false positive or false negative results due to technical error. Since we do not know the components of a RCL, two assays aimed at different components of the RCL may also increase the chance of RCL detection. shortly before vector harvest and also incorporate many of the safety features described above. 43, 44 This predicts a significantly greater safety profile than the MLV-based packaging cell lines but additional experience is required to establish whether these will consistently generate RCL-free vector products. Similarly, the propensity for RCL development in HIV-1 based vectors with significant differences in vector design, method of manufacture, or envelope will require bridging or full validation studies. Also, our findings do not extend to non-HIV-1 based lentiviruses or other retroviral vector systems.
In general, the RCL assay described here performed well. Of the 499 test articles analyzed there were 11 test articles that required resubmission due to technical issues. Three of the 11 required resubmission due to growth inhibition of the C8166-45 cells. Growth inhibition
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12 appeared to be related to the cellular product; there were no apparent issues of microbial contamination, samples were run on different assays, and were obtained from different investigators, and there was no evidence of p24 in the amplification phase media. The assays were repeated and increasing the number of cells at each split allowed the assays to be completed. Interestingly, the three products in questions (representing 3 of 499 products test or 0.6%) were CD4 T cell subset samples.
There were occasions when a single replicate well in p24 or PERT was above background will all other analyses for p24 and PERT were negative. This occurred in test articles and negative controls. Given the greater number of test articles run per assays compared to the negative control, there is no evidence of a higher frequency occurring in test articles. Both p24
ELISA and PERT assays are performed in plates, the most likely cause of the sporadic positive wells is aerosolization of positive control materials during set up and handling of the plates.
In addition to testing the T cell products, we collected data from the 26 clinical trials on post-infusion RCL testing. The US FDA requires subjects infused with lentiviral transduced products be monitored for RCL but currently there is no guidance requiring a specific assay.
Interestingly, each investigator independently chose qPCR for the VSV-G envelope as the preferred method for RCL monitoring. To date, no evidence of VSV-G envelope DNA has been reported in the subjects enrolled in the 26 clinical trials surveyed.
In summary, RCL has not been detected in third generation lentiviral vector products manufactured for clinical use. 29 We now add to that experience by analyzing T cell products used in cancer immunotherapy. In 460 products tested, using a vigorous biologic assay for RCL, there was no evidence of RCL. Participants evaluated post-infusion of T cell products were also without evidence of RCL exposure. These findings suggest that current vector design and vector
13 product screening provide a high level of assurance regarding the absence of replicating virus.
Therefore, screening T cell products for RCL does not add additional assurance of safety and should no longer be required when the lentiviral vector product has been successfully screened for RCL.
MATERIALS AND METHODS
Collection of Study Data. The NGVB is a National Heart, Lung and Blood Institute 
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The psi-gag PCR assays detects recombinants between the psi and gag viral genes and is described in Sastry et al. 11 with a modification to include a second PCR for human beta globin to validate that the test article DNA is of sufficient quantity and quality. The psi-gag PCR assay required PCR amplification followed by Southern blot analysis with a P 32 -labeled probes and added significant time to the assay turnaround. A validation study was performed demonstrating equivalency of the PERT assay 30 to the psi-gag PCR assay, samples after Characterization of recombinant events leading to the production of an ecotropic replication-competent retrovirus in a GP+envAM12-derived producer cell line. 
